Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist Activity

Area of Science:

• Immunology
• Computational Biology
• Drug Discovery

Background:

• Toll-like receptor 4 (TLR4) is crucial for immune responses.
• Current TLR4 activators are mostly lipopolysaccharide (LPS) derivatives.
• Novel TLR4 activators are needed for immunomodulation and adjuvant applications.

Purpose of the Study:

• To discover and optimize novel peptide activators of human TLR4.
• To explore computational design for identifying TLR4 ligands with unique structures.
• To develop potential alternatives to LPS-derived TLR4 agonists.

Main Methods:

• Computational design of 53 cyclic and linear peptides targeting TLR4 coreceptors (MD2 and CD14).
• Assessment of peptide activity using NF-κB reporter cell lines.
• Confirmation and quantification of binding to CD14 and MD2 via MicroScale Thermophoresis.
• Evaluation of cytokine induction in human whole blood, alone and with LPS.

Main Results:

• Successful identification of novel peptide activators for TLR4.
• Demonstration of computational design's efficacy in discovering structurally distinct TLR4 ligands.
• Validation of peptide-induced cytokine production in human whole blood.
• Peptides showed potential as standalone or synergistic immune modulators.

Conclusions:

• Computational design is an effective strategy for discovering novel TLR4 peptide activators.
• These peptides offer potential as easy-to-produce alternatives to LPS-derived molecules.
• The findings support the development of new immunomodulators and adjuvants targeting TLR4.